 SAN RAFAEL, Calif., Sept. 6, 2021 PRNewswire -- BioMarin Pharmaceutical Inc. NASDAQ: BMRN announced today that the U.S Food and Drug Administration FDA placed a clinical hold on the BMN 307 Phearless Phase 12 study. 